Date: 2011-05-16
Type of information: Licensing agreement
Compound: CP-4033
Company: Clavis Pharma (Norway) Translational Therapeutics (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
development
commercialisation
Action mechanism:
Disease: thyroid cancer - solid tumor
Details: Clavis Pharma and Translational Therapeutics have entered into a strategic licensing agreement regarding the development and commercialization of CP-4033. Translational Therapeutics will develop CP-4033 for use in the treatment of aggressive thyroid cancer and will evaluate the potential of CP-4033 for use in the treatment of other solid tumours. Clavis Pharma's intellectual property (IP) surrounding CP-4033 is complementary to Translational Therapeutics' IP estate around the use of ribavirin analogues for the treatment of human cancers and its companion diagnostic and therapeutic response monitoring technologies. The combined patent estate provides a solid foundation upon which to base a targeted cancer drug development programme.
Under the terms of the agreement, Translational Therapeutics will be responsible for all future development of CP-4033. Clavis Pharma will receive a minority equity stake in Translational Therapeutics and potential future milestone and royalty payments. Further terms of the agreement were not disclosed.
Financial terms: Financial details were not disclosed.
Latest news:
